- Home
- Publications
- Publication Search
- Publication Details
Title
Prostate Cancer Immunotherapy—Finally in From the Cold?
Authors
Keywords
-
Journal
Current Oncology Reports
Volume 23, Issue 8, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-06-14
DOI
10.1007/s11912-021-01084-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Impact of baseline serum IL-8 on metastatic hormone-sensitive (mHSPC) prostate cancer outcomes in the phase III CHAARTED trial (E3805).
- (2020) Lauren Christine Harshman et al. JOURNAL OF CLINICAL ONCOLOGY
- Update on KEYNOTE-199, cohorts 1-3: Pembrolizumab (pembro) for docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC).
- (2020) Emmanuel S. Antonarakis et al. JOURNAL OF CLINICAL ONCOLOGY
- T-Cell Infiltration and Adaptive Treg Resistance in Response to Androgen Deprivation With or Without Vaccination in Localized Prostate Cancer
- (2020) Aleksandar Z. Obradovic et al. CLINICAL CANCER RESEARCH
- First-in-human phase I study of HPN424, a tri-specific half-life extended PSMA-targeting T-cell engager in patients with metastatic castration-resistant prostate cancer (mCRPC).
- (2020) Johanna C. Bendell et al. JOURNAL OF CLINICAL ONCOLOGY
- KEYNOTE-199 cohorts (C) 4 and 5: Phase II study of pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC).
- (2020) Christopher J. Hoimes et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I, open-label, multicenter study to assess the safety, pharmacokinetics, and preliminary antitumor activity of AZD4635 both as monotherapy and in combination in patients with advanced solid malignancies: Results from prostate cancer patients (NCT02740985).
- (2020) Emerson A. Lim et al. JOURNAL OF CLINICAL ONCOLOGY
- Biomarker analysis from the KEYNOTE-199 trial of pembrolizumab in patients (pts) with docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC).
- (2020) Emmanuel S. Antonarakis et al. JOURNAL OF CLINICAL ONCOLOGY
- Preliminary dose escalation results from a phase I/II, first-in-human study of MGC018 (anti-B7-H3 antibody-drug conjugate) in patients with advanced solid tumors.
- (2020) John D. Powderly et al. JOURNAL OF CLINICAL ONCOLOGY
- Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors
- (2020) Kurt A. Schalper et al. NATURE MEDICINE
- High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade
- (2020) Kobe C. Yuen et al. NATURE MEDICINE
- Olaparib for Metastatic Castration-Resistant Prostate Cancer
- (2020) Johann de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- The PI3K-AKT-mTOR Pathway and Prostate Cancer: At the Crossroads of AR, MAPK, and WNT Signaling
- (2020) Boris Y. Shorning et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Current Status and Future Perspectives of Checkpoint Inhibitor Immunotherapy for Prostate Cancer: A Comprehensive Review
- (2020) Tae Jin Kim et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial
- (2020) Padmanee Sharma et al. CANCER CELL
- Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors
- (2020) Karim Fizazi et al. EUROPEAN UROLOGY
- High intratumoral CD8 + T‐cell infiltration is associated with improved survival in prostate cancer patients undergoing radical prostatectomy
- (2020) Yuanquan Yang et al. PROSTATE
- Phase 1 study of PSMA ADC, an antibody-drug conjugate targeting prostate-specific membrane antigen, in chemotherapy-refractory prostate cancer
- (2019) Daniel P. Petrylak et al. PROSTATE
- Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
- (2019) Karim Fizazi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer
- (2019) James L. Gulley et al. JOURNAL OF CLINICAL ONCOLOGY
- Ligand-inducible, prostate stem cell antigen (PSCA)-directed GoCAR-T cells in advanced solid tumors: Preliminary results from a dose escalation.
- (2019) Carlos Roberto Becerra et al. JOURNAL OF CLINICAL ONCOLOGY
- Prostatic Acid Phosphatase (PAP) Predicts Prostate Cancer Progress in a Population-Based Study: The Renewal of PAP?
- (2019) Huan Xu et al. DISEASE MARKERS
- Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
- (2019) Kim N. Chi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase 2 clinical trial of TORC1 inhibition with everolimus in men with metastatic castration-resistant prostate cancer
- (2019) Daniel J. George et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Differences in Tumor Microenvironment Dictate T Helper Lineage Polarization and Response to Immune Checkpoint Therapy
- (2019) Shiping Jiao et al. CELL
- Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study
- (2019) Emmanuel S. Antonarakis et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study
- (2018) A R Hansen et al. ANNALS OF ONCOLOGY
- The “less-is-more” in therapeutic antibodies: Afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity
- (2018) Natasha A. Pereira et al. mAbs
- Clinical implications of PTEN loss in prostate cancer
- (2018) Tamara Jamaspishvili et al. Nature Reviews Urology
- Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer
- (2018) Maha Hussain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Role of mTOR Signaling in Tumor Microenvironment: An Overview
- (2018) Fabiana Conciatori et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer
- (2018) Daniel Nava Rodrigues et al. JOURNAL OF CLINICAL INVESTIGATION
- IL-23 secreted by myeloid cells drives castration-resistant prostate cancer
- (2018) Arianna Calcinotto et al. NATURE
- Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer
- (2018) Daniel Nava Rodrigues et al. JOURNAL OF CLINICAL INVESTIGATION
- A review on the interactions between the tumor microenvironment and androgen receptor signaling in prostate cancer
- (2018) Milly J. McAllister et al. Translational Research
- Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss
- (2018) Johann S. de Bono et al. CLINICAL CANCER RESEARCH
- Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer
- (2017) Tomasz M. Beer et al. JOURNAL OF CLINICAL ONCOLOGY
- Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment
- (2017) James L. Gulley et al. JNCI-Journal of the National Cancer Institute
- VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer
- (2017) Jianjun Gao et al. NATURE MEDICINE
- The inflammatory microenvironment and microbiome in prostate cancer development
- (2017) Karen S. Sfanos et al. Nature Reviews Urology
- Combining intratumoral Treg depletion with androgen deprivation therapy (ADT): preclinical activity in the Myc-CaP model
- (2017) Ying-Chun Shen et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
- (2017) Bertrand Routy et al. SCIENCE
- Modulation of cabozantinib efficacy by the prostate tumor microenvironment
- (2017) Manisha Tripathi et al. Oncotarget
- Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases
- (2017) Helen Ha et al. Theranostics
- Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment
- (2017) James L. Gulley et al. JNCI-Journal of the National Cancer Institute
- Safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity of the oral AKT inhibitor GSK2141795 (GSK795) in a phase I first-in-human study.
- (2017) H. A. Burris et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunogenicity and efficacy of the novel cancer vaccine based on simian adenovirus and MVA vectors alone and in combination with PD-1 mAb in a mouse model of prostate cancer
- (2016) Federica Cappuccini et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1
- (2016) Matthew Smith et al. JOURNAL OF CLINICAL ONCOLOGY
- Cutting Edge: Adenosine A2a Receptor Signals Inhibit Germinal Center T Follicular Helper Cell Differentiation during the Primary Response to Vaccination
- (2016) Shirdi E. Schmiel et al. JOURNAL OF IMMUNOLOGY
- Phase I Trial of Anti-PSMA Designer CAR-T Cells in Prostate Cancer: Possible Role for Interacting Interleukin 2-T Cell Pharmacodynamics as a Determinant of Clinical Response
- (2016) Richard P. Junghans et al. PROSTATE
- mTOR Inhibitors in Castration-Resistant Prostate Cancer: A Systematic Review
- (2016) Cara M. Statz et al. Targeted Oncology
- Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer
- (2016) Matthew I. Milowsky et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy
- (2016) Maxine Sun et al. JAMA Oncology
- Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications
- (2015) Dana E. Rathkopf et al. CANCER
- Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome
- (2015) D. GuhaThakurta et al. CLINICAL CANCER RESEARCH
- Final analysis of COMET-2: Cabozantinib (Cabo) versus mitoxantrone/prednisone (MP) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with moderate to severe pain who were previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E).
- (2015) Ethan M. Basch et al. JOURNAL OF CLINICAL ONCOLOGY
- Correlation between frequencies of blood monocytic myeloid-derived suppressor cells, regulatory T cells and negative prognostic markers in patients with castration-resistant metastatic prostate cancer
- (2014) Manja Idorn et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
- (2014) Eugene D Kwon et al. LANCET ONCOLOGY
- Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study
- (2013) S. F. Slovin et al. ANNALS OF ONCOLOGY
- STEAP1 protein overexpression is an independent marker for biochemical recurrence in prostate carcinoma
- (2013) Shadia M Ihlaseh-Catalano et al. HISTOPATHOLOGY
- Human Prostatic Acid Phosphatase: Structure, Function and Regulation
- (2013) Sakthivel Muniyan et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Mutational heterogeneity in cancer and the search for new cancer-associated genes
- (2013) Michael S. Lawrence et al. NATURE
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
- (2013) C. Parker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment
- (2013) N. Iida et al. SCIENCE
- STEAP1 is overexpressed in prostate cancer and prostatic intraepithelial neoplasia lesions, and it is positively associated with Gleason score
- (2013) Inês M. Gomes et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
- (2012) Karim Fizazi et al. LANCET ONCOLOGY
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact of tumour volume on the potential efficacy of therapeutic vaccines
- (2011) J. L. Gulley et al. Current Oncology
- T Cell Surveillance of Oncogene-Induced Prostate Cancer Is Impeded by T Cell-Derived TGF-β1 Cytokine
- (2011) Moses K. Donkor et al. IMMUNITY
- Prostate Stem Cell Antigen: A Jekyll and Hyde Molecule?
- (2010) N. Saeki et al. CLINICAL CANCER RESEARCH
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prostate cancer lesions are surrounded by FOXP3+, PD-1+ and B7-H1+ lymphocyte clusters
- (2009) Kathleen Ebelt et al. EUROPEAN JOURNAL OF CANCER
- Tumor Recognition and Self-Recognition Induce Distinct Transcriptional Profiles in Antigen-Specific CD4 T Cells
- (2009) D. Getnet et al. JOURNAL OF IMMUNOLOGY
- Enhanced Functionality of CD4+CD25highFoxP3+ Regulatory T Cells in the Peripheral Blood of Patients with Prostate Cancer
- (2008) J. Yokokawa et al. CLINICAL CANCER RESEARCH
- Prostate tumor progression is mediated by a paracrine TGF-β/Wnt3a signaling axis
- (2008) X Li et al. ONCOGENE
- The tumor microenvironment and its role in promoting tumor growth
- (2008) T L Whiteside ONCOGENE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started